The RNOH will remain the UK’s leading specialist orthopaedic hospital, further enhancing its international profile for outstanding patient care, research and education

Pharmacy and medicines optimisation

The RNOH Pharmacy provides a comprehensive array of pharmacy services with the overall aim of ensuring safe, effective and economical use of medicines throughout the Trust as well as supporting education and training and promoting research.

The pharmacy department is closely involved in all stages of medicine use from negotiating contracts for the purchase of medicines through to assessing the outcomes of medicines in the clinical setting.

The Chief Pharmacist holds overall responsibility for ensuring high-quality medicines optimisation and is the named lead for medication safety.

The Drugs and Therapeutics Committee (DTC) oversees medicines optimisation issues including the Trust Formulary and assessment of new drugs in combination with the North Central London Joint Formulary Committee (NCL JFC). The DTC in combination with the Trust Clinical Quality and Governance Committee also focuses on monitoring medication safety measure and devising measure of improving safer practice.

The pharmacy department is based at the Stanmore site only (see below for opening hours).

Patient Support Services

All patients have access to the patient medicines helpline to assist with any medicines related enquiry both prior to admission and following discharge (contact 020 8909 5832).

Service Managers

Mr Ashik Shah, Chief Pharmacist
Email: ashik.shah@rnoh.nhs.uk

Mr Gaurang Purohit, Deputy Chief Pharmacist (Formulary, Research & Governance)
Email: Gaurang.Purohit@rnoh.nhs.uk

Mrs Elsy Gomez-Campos, Deputy Chief Pharmacist (Clinical Services)
Email: Elsy.Gomez-Campos@rnoh.nhs.uk

RNOH Pharmacy opening hours:

Monday to Friday: 9am to 5pm
Saturday: 9am to 3pm

Outside of the above normal working hours, an emergency on-call service may be accessed via the RNOH switchboard.

Useful documents:Size
UCLH guideline on statin prescribing170.72 KB
UCLH guideline on angiotensin II receptor blockers for hypertension and heart failure105.75 KB
Shared Care Guideline for the use of Denosumab62.02 KB
Antimicrobial Policy1.04 MB
RNOH enabling statement for OPAT81.55 KB
How helpful did you find this page?
Not helpful
Very helpful *
Required fields *

Our Services